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Elderly patients are recommended to have a reduced starting dose (300mgm
 2 once every 3 weeks) of irinotecan monotherapy.
The aims of this analysis are to compare toxicity and survival according to age, performance status (PS), gender and prior radical
pelvic radiotherapy (RT). The primary end points were overall survival and an irinotecan-specific toxicity composite end point (TCE)
defined as the occurrence of grade 3 or 4 diarrhoea, neutropenia, febrile neutropenia, fever, infection or nausea and vomiting.
Between 1997 and 2003, 339 eligible patients with advanced colorectal cancer (CRC) progressing on or within 24 weeks of
completing fluoropyrimidine-based chemotherapy were prospectively registered in a multicentre randomised trial. All patients
commenced irinotecan at 350mgm
 2 once every 3 weeks. There were no differences in proportions of patients developing TCE by
age (o70 vs X70:37.8 vs 45.8%; P¼0.218), PS (0–1 vs 2:39.3 vs 41.5%; P¼0.793) or prior RT (RT vs no RT:45.1 vs 38.5%;
P¼0.377). Males experienced more toxicity than females (44.3 vs 32.6%; P¼0.031), but this was not significant after controlling for
other co-variates (P¼0.06). Patients aged X70 had similar objective responses (11.1 vs 9%; P¼0.585) and survival (median 9.4 vs 9
months; log rank P¼0.74) compared to younger patients. Elderly patients derive the same benefit without experiencing more
toxicity with second-line irinotecan treatment for advanced CRC. Our data do not support the recommendation to reduce the
starting dose for the elderly patients.
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Elderly patients with colorectal cancer (CRC) have the same benefit
from fluorouracil-based chemotherapy as younger patients in both
adjuvant (Sargent et al, 2001; Sundararajan et al, 2002) and
advanced disease (Popescu et al, 1999) settings. The role of
irinotecan is now established in patients with fluoropyrimidine-
refractory CRC based on two randomised studies demonstrating
survival benefit over best supportive care or alternative schedules
of infused fluorouracil (Cunningham et al, 1998; Rougier et al,
1998). Despite its efficacy, irinotecan produces toxicities that could
be potentially life-threatening, especially when given with bolus 5-
FU/leucovorin (LV) (Rothenberg et al, 2001). It is currently
unclear whether elderly patients tolerate irinotecan poorly and
whether a reduced starting dose for these patients is preferable.
Moreover, the potential risks need to be weighed against the
expected benefits of receiving irinotecan, especially in this older
age group.
The dose adjustment guideline for irinotecan monotherapy,
produced by the manufacturer which is in general circulation with
clinicians, recommends a reduced starting dose of 300mgm
 2
once every 3 weeks for patients aged 470 years with World Health
Organisation (WHO) performance status (PS) 2. This guideline
is based on the two pivotal second-line studies – both recommen-
ded 300mgm
 2 for patients aged X70 or PS 2 as these factors
were previously recognised risk factors for developing toxicity
(Cunningham et al, 1998; Rougier et al, 1998). One further
phase III study comparing two irinotecan dose regimens in
second-line therapy of metastatic CRC also made the same
recommendation (Fuchs et al, 2003). However, none of these
studies reported any data that prompted this recommendation of a
reduced starting dose (300mgm
 2) for these particular patient
populations. In addition, it is generally accepted that patients who
had previous radical pelvic radiotherapy (RT) are also at risk of
developing severe toxicity with irinotecan, especially diarrhoea.
The aims of our analysis are to compare toxicity and survival
according to age, PS, gender and prior radical pelvic RT in a group
of patients treated within a prospective randomised controlled
trial, all of whom commenced irinotecan at a dose of 350mgm
 2
given every 3 weeks.
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lPATIENTS AND METHODS
We performed a phase III multicentre prospective randomised
controlled trial recruiting patients from six oncology centres in the
United Kingdom. The primary efficacy end point of this study has
been reported previously (Lal et al, 2004). The eligibility criteria
included: locally advanced or metastatic histologically proven
colorectal cancer that progressed on or within 24 weeks of
fluorouracil, raltitrexed or oral fluoropyrimidine-based che-
motherapy; WHO PS p2; bidimensionally measurable disease
assessed by chest X-ray or computed tomography (CT) and
satisfactory haematological, renal and liver functions. Patients who
had received previous adjuvant chemotherapy and up to a
maximum of three lines of palliative chemotherapy as well as
those with no measurable disease were permitted into the study.
All patients fulfilling the eligibility criteria were prospectively
registered for the trial. Patients who achieved a radiological
objective response or disease stabilisation after 24 weeks of
irinotecan were then randomly assigned to either stop irinotecan
or continue irinotecan on a 1:1 basis using random permuted
blocks. Patients were stratified according to number of previous
lines of treatment. The protocol was approved by the Scientific and
Research Ethics Committee of the participating institutions as well
as the London Multicentre Research Ethics Committee. Written
informed consent was obtained from each patient at registration.
Patients were treated with irinotecan 350mgm
 2 intravenously
over 30min every 3 weeks for eight cycles. No reduced starting
dose was recommended in the protocol for patients aged X70
years, WHO PS 2 or previous radical pelvic RT. Toxicity was
measured using National Cancer Institute-Common Toxicity
Criteria version 2. Radiological assessment with CT scan was
made after every four cycles of irinotecan. Radiological tumour
response was evaluated according to WHO Criteria (Miller et al,
1981). Complete response (CR) was defined as the complete
disappearance of all measurable lesions, without the appearance of
new lesion(s). Partial response (PR) was defined as a reduction of
bi-dimensional lesions by X50% of the sum of the products of the
largest perpendicular diameters of each measurable lesion and no
progression in other lesions or the appearance of any new lesions.
Stable disease (SD) was defined as a o50% reduction of tumour
volume or a o25% increase of the volume of one or more
measurable lesions, with no new lesions. Progressive disease (PD)
was defined as an increase of X25% of the size of at least one bi-
dimensionally measurable lesion, the appearance of new lesion(s),
and/or the onset of ascites or pleural effusion with cytological
confirmation.
STATISTICAL CONSIDERATIONS
In this secondary analysis of the trial, the primary objectives were
to compare toxicity and survival in the whole cohort of registered
patients with the following subgroups which were set a priori: (i)
aged o70 vs X70 years; (ii) PS 0–1 vs 2; (iii) male vs female and
(iv) previous pelvic RT (X45Gy total dose) vs no pelvic RT. The
primary end points were irinotecan-specific toxicity composite end
point (TCE) and overall survival (OS). TCE was defined as the
occurrence of either grade 3 or 4 diarrhoea, neutropenia, febrile
neutropenia, fever, infection or nausea and vomiting. These
toxicities were components of the gastrointestinal syndrome that
caused early 60-day mortality related to irinotecan therapy
(Rothenberg et al, 2001). Logistic regression modelling was used
to compare different groups in the frequency of developing TCE.
Overall survival was calculated from the date of registration until
death from any cause or censored at last follow-up. Both time to
developing first TCE and OS were calculated using the Kaplan–
Meier method (Kaplan and Meier, 1958) and were compared
between the groups using the log-rank test (Peto and Peto, 1972).
Univariate analysis was performed using logistic regression and
the log-rank test to identify characteristics predictive for
occurrence of TCE and survival, respectively. The predictive
factors analysed for effect were age (o70 vs X70), PS (0–1 vs 2),
gender (male vs female), previous pelvic RT (yes vs no), number of
metastatic sites (0 or 1 vs 41), baseline serum alkaline
phosphatase (pupper limit of normal range (ULN) vs 4ULN),
bilirubin (as a continuous variable as few patients had elevated
bilirubin level due to trial eligibility), haemoglobin (p11g/dl vs
411gdl
 1) and white blood cell (p11 10
9l vs 411 10
9l
 1)
levels. Apart from the a priori defined comparison groups, other
factors were chosen because of their prognostic value in patients
treated with 5-FU based chemotherapy for metastatic CRC (Kohne
et al, 2002). Multivariate survival analysis was performed using
Cox’s proportional hazards model (Cox, 1972) and corrected for all
the significant prognostic factors. All end points were updated in
December 2003. Analyses were performed using SPSS package
version 12 (SPSS Inc., Chicago, IL, USA) and two-sided P-values
o0.05 were considered statistically significant.
RESULTS
Between November 1997 and May 2003, 348 patients were
prospectively registered into this study. A total of 55 patients with
responding or SD after eight cycles of irinotecan were randomised
to stop irinotecan (n¼30) or continue until disease progression
(n¼25). The efficacy of the randomisation part of the study is the
subject of a separate publication. In this current analysis, nine
(2.6%) patients were excluded due to reduced starting dose
(300mgm
 2, n¼5), ineligible patient (n¼1), death before
starting treatment (n¼1) and no clinical data (n¼2); therefore,
339 patients treated with irinotecan 350mgm
 2 once every 3
weeks were analysed.
Table 1 shows the baseline characteristics at registration for the
whole group. The median age for patients in the o70 years age
group was 58 (range¼29–69) whereas the median age for those in
the X70 years age group was 72 (range¼70–80). Only one patient
had PS 3. Table 2 shows the incidences of maximum grade adverse
events occurring during any cycle in the whole group. Although
the elderly had a higher incidence of neutropenia (P¼0.0228), the
incidences of infection, fever and febrile neutropenia were not
significantly increased. Patients who had prior RT did not have a
significantly higher incidence of diarrhoea compared to those who
did not receive prior RT (P¼0.0921). Table 3 shows the number of
patients developing TCE according to age, PS, gender and prior
radical pelvic RT. There were no significant differences in the
proportions of patients developing TCE by age, PS or prior RT
(P40.05). Time to occurrence of TCE was also similar by age (log
rank P¼0.222; Figure 1) and PS (P¼0.424; Figure 2). Males
experienced more toxicity than females (44.3 vs 32.6%; P¼0.031),
but this was not significant after controlling for other co-variates
(P¼0.06) in multivariate logistic regression modelling. Baseline
bilirubin level was not significantly associated with TCE
(P¼0.149).
For the whole group, the objective response rate was 9.4% (95%
confidence interval (CI): 6.3–12.6%). Table 4 shows the objective
responses in patients aged o70 and X70 years with no differences
between the two age groups. For the whole group, the median
survival was 9.1 months and 1-year survival was 35.3% (95% CI:
30.1–40.5%). There was no difference in survival between patients
aged o70 years and X70 years (log-rank test P¼0.74; Figure 3).
Table 5 shows the multivariate survival analysis. Number of
metastatic sites, serum alkaline phosphatase, haemoglobin, white
blood cell count and prior pelvic RT were significant prognostic
factors. Performance status (P¼0.092) and gender (P¼0.512)
were not significant prognostic factors. There was no difference in
survival between patients who developed the TCE and those who
did not (P¼0.317).
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lDISCUSSION
Our study included 339 fluoropyrimidine and thymidylate
synthase inhibitor-resistant CRC patients, all treated uniformly
at 350mgm
 2 of irinotecan once every 3 weeks and this represents
the largest single study with second-line irinotecan monotherapy
reported to our knowledge. In this study we have shown that
patients aged 70 or over had similar benefit and toxicity to
irinotecan as younger patients. Poor PS and previous pelvic RT did
not influence the incidence of irinotecan-related severe toxicity in
these patients.
Although survival is the most important end point in evaluating
new agents, insistence on its use as the only end point in clinical
trials can result in the need for thousands of patients to be studied.
Accordingly, composite end points have been increasingly used to
increase the overall event rate and thereby reduce the number of
patients needed to test specific hypotheses. The use of composite
end points has resulted in widespread acceptance of therapies
in heart failures and acute coronary syndrome (Cannon, 1997),
although this approach is less utilised in oncological studies. To be
used as part of composite end point, nonfatal end points should be
clinically meaningful and related to an adverse outcome (Cannon,
1997). In our analysis, we were interested in evaluating irinotecan-
related toxicity in predefined patient populations. The incidences
of individual grade 3 & 4 toxicity were low (Table 2), despite our
study being one of the largest conducted to date in this setting and
this prevented us from comparing individual toxicities by specific
patient groups. The gastrointestinal syndrome, comprised of
diarrhoea, neutropenia, infection and nausea and vomiting, has
been shown to be associated with early treatment-related or
exacerbated deaths with irinotecan when used with bolus 5-FU/
leucovorin (Rothenberg et al, 2001). These toxicities are well
recognised as serious toxicities associated with irinotecan treat-
ment and thus justified their use as components of our TCE.
The dose adjustment guidelines for irinotecan, produced by the
manufacturer, recommend a reduced starting dose of 300mgm
 2
in patients aged X70 years with PS 2. These guidelines have not,
however, been incorporated into the Summaries of Product
Characteristics. We have sought to use our independent data set
to validate or refute these recommendations. Elderly patients are
perceived to tolerate treatment more poorly and the benefits are
less certain in elderly patients. In a systematic review of managing
CRC in elderly patients, it was concluded that there is good
evidence to support patients p80 years of age having similar OS
benefits with adjuvant 5-FU-based chemotherapy for colon cancer
and with palliative first-line monotherapy for colorectal cancer, to
younger patients (Au et al, 2003). Moreover, advancing age was
not found to be related to the incidences of grade 3–4 nausea or
vomiting, stomatitis or diarrhoea in patients treated with 5-FU-
based adjuvant chemotherapy, although more leucopenia occurred
Table 1 Baseline characteristics at registration for the whole group
Characteristics Number of patients
Total number of patients 339
Median age (years) 62
Range 29–80
o70 years old 267 (78.8%)
X70 years old 72 (21.2%)
Gender
Male 201 (59.3%)
Female 138 (40.7%)
Performance status
0 90 (26.6%)
1 205 (60.5%)
2 40 (11.8%)
3 1 (0.3%)
Unknown 3 (0.9%)
Primary tumour sites
Colon 209 (61.7%)
Rectum 88 (26%)
Rectosigmoid junction 20 (5.9%)
Synchrounous 13 (3.8%)
Others 4 (1.2%)
Unknown 5 (1.5%)
Involved disease sites
Liver 246 (72.6%)
Lung 143 (42.2%)
Peritoneum 55 (16.2%)
Primary tumour in situ or local recurrence 107 (31.6%)
Previous radical pelvic radiotherapy
Yes 51 (15%)
No 288 (85%)
Table 2 Incidences of grade 3 or 4 toxicities
Toxicities
Whole group
(n¼339)
o70 years
(n¼267)
X70 years
(n¼72)
Male
(n¼201)
Female
(n¼138)
PS 0–1
(n¼295)
PS 2–3
(n¼41)
Previous RT
(n¼51)
No previous
RT (n¼288)
Anaemia 17 (5%) 15 (6%) 2 (3%) 10 (5%) 7 (5%) 16 (5%) 1 (2%) 3 (6%) 14 (5%)
Neutropenia 83 (24%) 58 (22%) 25 (35%) 61 (30%) 22 (16%) 72 (24%) 11 (27%) 12 (24%) 71 (25%)
Thrombocytopenia 12 (4%) 8 (3%) 4 (6%) 7 (3%) 5 (4%) 10 (3%) 2 (5%) 3 (6%) 9 (3%)
Febrile neutropenia 4 (1%) 2 (0.7%) 2 (3%) 3 (1%) 1 (0.7%) 3 (1%) 1 (2%) 0 (0%) 4 (1%)
Diarrhoea 53 (16%) 42 (16%) 11 (15%) 35 (17%) 18 (13%) 43 (15%) 9
a (22%) 12 (24%) 41 (14%)
Nausea and vomiting 18 (5%) 15 (6%) 3 (4%) 10 (5%) 8 (6%) 17 (6%) 1 (2%) 2 (4%) 16 (6%)
Infection 20 (6%) 18 (7%) 2 (3%) 14 (7%) 6 (4%) 17 (6%) 3 (7%) 4 (8%) 16 (6%)
Fever 13 (4%) 12 (5%) 1 (1%) 9 (5%) 4 (3%) 11 (4%) 2 (5%) 1 (2%) 12 (4%)
Lethargy 72 (21%) 57 (21%) 15 (21%) 45 (22%) 27 (20%) 60 (20%) 11 (27%) 10 (20%) 62 (22%)
PS: performance status. RT: radiotherapy.
aOne patient with grade 3–4 diarrhoea had unknown baseline performance status.
Table 3 Number of patients developing toxicity composite endpoint
according to age, performance, sex and previous radical pelvic radiotherapy
Comparison groups
Number of patients
reaching TCE v
2-test P
Ageo70 101/267 (37.8%) 0.218
AgeX70 33/72 (45.8%)
Performance status 0–1 116/295 (39.3%) 0.793
Performance status 2–3 17/41 (41.5%)
Male 89/201 (44.3%) 0.031
Female 45/138 (32.6%)
Pelvic radiotherapy 23/51 (45.1%) 0.377
No pelvic radiotherapy 111/288 (38.5%)
TCE: toxicity composite end point.
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lwith increasing age (Sargent et al, 2001). In the advanced disease
setting, there was also no increase in toxicity in patients 470 years
of age compared with younger patients (Popescu et al, 1999).
However, the previously mentioned systematic review only
included studies evaluating first-line palliative chemotherapy (Au
et al, 2003). The effect of age in the second-line treatment of
advanced CRC is much less evaluated. Our study showed that
patients aged 70 or over had a similar survival and radiological
response rate compared to younger patients without any increase
in toxicity. However, the maximum age of patients recruited into
our study was 80; therefore, our findings may not extend to
octogenarians and nonagenarians.
In a pooled analysis of five phase II trials, 455 patients with
metastatic CRC progressing on 5-FU were assessed for clinical
efficacy and/or tolerance to irinotecan given at 350mgm
 2 every 3
weeks (Freyer et al, 2000). However, in three of these studies,
treatment included an enkephalinase inhibitor against diarrhoea,
racecadotril, which was assessed as the primary therapeutic
intervention. In this pooled analysis, age was not significantly
associated with disease response or stabilisation, although patients
younger than 58 years old had worse progression-free survival
compared to older patients. Overall survival was not assessed in
this study (Freyer et al, 2000). Age was also not related to the
occurrence of grade 3–4 neutropenia or diarrhoea (Freyer et al,
2000), consistent with our data. In a retrospective analysis of a
randomised study evaluating a biweekly bolus irinotecan/5-FU/LV
regimen, patients aged X70 (n¼17) did not suffer higher
frequency of grades 3–4 toxicity compared to those aged under
70 (n¼101) (Comella et al, 2003). Survival was also unaffected by
age of patients. In another multicentre phase II study, it has been
shown that chemotherapy with irinotecan or oxaliplatin-based
treatment was feasible with manageable toxicity in the elderly
(Aparicio et al, 2003). Similar data have also been found in first-
line settings (Mitry et al, 2003; Rougier et al, 2003).
A meta-analysis of 2448 patients in five NCCTG clinical trials,
using bolus schedules of 5-FU and LV, reported significantly more
stomatits, diarrhoea, alopecia and leucopenia in women compared
to men (Sloan et al, 2002). In addition, women experienced more
toxicity than men consistently across all cycles of treatment and
for all toxicities despite dose reduction after first cycles. These
results suggested that women might be intrinsically more sensitive
to 5-FU. However, this gender difference in toxicity is not limited
to bolus 5-FU/LV schedules, but also extends to infused 5-FU
(Tebbutt et al, 2003). In our analysis, we evaluated whether there
were gender differences in efficacy and developing toxicity to
irinotecan. Male sex was associated with a greater incidence of
TCE, although this was not significant after controlling for other
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Figure 1 Time of occurrence of toxicity composite end point by age
groups.
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Figure 2 Time to occurrence of toxicity composite end point by
performance status groups.
Table 4 Objective responses for patients aged o70 compared to those
aged X70
o70 years old
(n¼267)
X70 years
old (n¼72) P
Complete response 0 (0%) 1 (1.4%)
Partial response 24 (9%) 7 (9.7%)
Stable disease 84 (31.5%) 28 (38.9%)
Progressive disease 159 (59.6%) 36 (50%)
Objective response rate
(95% confidence interval)
9% (5.6–12.4%) 11.1% (4.9–20.7%) 0.585
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Figure 3 Overall survival by age groups.
Table 5 Multivariate analysis of prognostic factors on overall survival
Factors
Hazard
ratio
95% confidence
interval P
41 metastatic sites 1.275 1.01–1.61 0.041
Alkaline phosphatase 4ULN 1.951 1.519–2.506 o0.001
Haemoglobin p11gl
 1 1.65 1.247–2.188 o0.001
White blood cell
411 10
9l
 1
1.662 1.248–2.212 0.001
Previous pelvic radiotherapy 1.684 1.213–2.339 0.002
Performance status 0.092
Age
a 0.734
Sex
a 0.512
aUnivariate analyses. ULN: upper limit of normal.
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lco-variates. No survival differences were seen between males and
females. However, few other published data are available evaluat-
ing gender difference to irinotecan therapy (Innocenti et al, 2004).
It is commonly accepted that abdomino-pelvic RT is associated
with a greater incidence of irinotecan toxicities and many
clinicians would elect to give a reduced starting dose. Previous
RT has been shown to result in a greater incidence of grades 3–4
diarrhoea with irinotecan (P¼0.046) (Freyer et al, 2000), although
this observation was only of borderline significance. Our data and
others did not support such a notion (Venook et al, 2003).
In our study, baseline serum bilirubin level did not influence the
occurrence of TCE (P¼0.149), although one has to note that our
eligibility criteria would exclude patients with bilirubin level above
1.25 and 1.5 times the ULN in the absence and presence of liver
metastasis respectively. A recent study has also found that baseline
serum bilirubin did not reliably predict overall irinotecan-related
toxicity in patients treated with irinotecan monotherapy within a
phase III trial (Meyerhardt et al, 2004). Significant elevation of
bilirubin is however associated with higher incidences of
irinotecan-related toxicity (Raymond et al, 2002; Venook et al,
2003) and precludes normal starting dose of irinotecan to be used.
Most recent research effort has focussed on UGT1A1 polymorph-
ism as a determinant of irinotecan toxicity. Irinotecan is converted
by carboxyl-esterase to its active metabolite, SN-38, which in
turn undergoes glucuronidation by UDP-glucuronosyltransferase
(UGT). UGT1A1 is the enzyme responsible for bilirubin glucur-
onidation of SN-38. UGT1A1 polymorphisms result in reduced
UGT1A1 activity giving rise to genetic hyperbilirubinaemic
syndromes such as Crigler–Najjar types I & II and Gilbert’s
syndrome and can lead to reduced gluronidation of SN-38. It has
been found that patients either heterozygous or homozygous for
UGT1A1*28, a variant sequence in the promoter region experi-
enced more severe toxicity to irinotecan and had higher area under
curve (AUC) SN-38 ratio compared to SN-38 glucuronide ratio
(Ando et al, 2000, 2002; Iyer et al, 2002; Innocenti et al, 2004)
Thus, interindividual differences in susceptibility to irinotecan
toxicity can be partly explained by UGT1A1 mutation. However,
whether starting with a reduced dose of irinotecan based on
UGT1A1 polymorphism is an appropriate strategy requires
prospective evaluation.
In our study, we have confirmed that the prognostic impor-
tances of some clinical and biological factors found in 5-FU based
chemotherapy (Kohne et al, 2002) were also valid in irinotecan
chemotherapy, that is, elevated alkaline phosphatase, low haemo-
globin, elevated white blood cell count and 41 metastatic sites.
Performance status 2 was not significantly associated with worse
survival. We are unable to explain the reason why previous radical
RT was a poor prognostic factor and this could be a chance finding
that requires confirmation in an independent data set.
In conclusion, elderly and PS 2 patients derive the same benefit
without experiencing more toxicity with second-line irinotecan
treatment for advanced colorectal cancer. Pelvic RT did not result
in additional toxicity. Our data do not support the recommenda-
tions to give a reduced starting dose to elderly and PS 2 patients.
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